CASE REPORT

PRIMARY LYMPHOMA OF THE LIVER TREATED BY EXTENDED HEPATECTOMY AND CHEMOTHERAPY: A CASE REPORT

Eleazar Chaib, Katia Ramos Moreira Leite, Willian Abrão Saad and Joaquim Gama-Rodrigues

Primary lymphomas of the liver are notably rare, and as a result in the past, and even quite recently, they have been diagnosed only at postmortem examination. About 70 patients with this disease have been described in the past 40 years in the literature, but only 16 patients, including our case, have been treated surgically so far.

The predominant histologic description of these lesions includes B-cell lymphomas of the so-called histiocytic type or the large differentiated cell. Other variants reported include the lymphocytic type, reticulum cell sarcoma, undifferentiated non-Hodgkin’s lymphoma, and centroblastic-centrocytic lymphoma.

We report a case of a patient with primary malignant lymphoma of the liver, of B-cell origin, who underwent surgical treatment followed by systemic chemotherapy.

CASE REPORT

A 33-year-old white man was referred for evaluation of an epigastric mass first noted 3 months previously. Associated with the mass were lethargy, anorexia, and a 6.5 kg weight loss. The patient denied experiencing fevers, chills, night sweats, nausea, or vomiting. The past medical history was benign, and the patient was on no medications. The physical examination was benign, and the patient was on no medications. The physical examination revealed a large palpable, smooth, nontender mass in the right hypochondrium that extended from the costal arch to the umbilicus. The spleen was not palpable, and there were no other abdominal masses. There was no lymphadenopathy. The remainder of the examination was normal.

Laboratory studies showed the following: serum glutamic oxaloacetic transaminase (SGOT) 32 IU/L, lactic dehydrogenase 1190 IU/L, bilirubin direct 0.4 mg/dL, bilirubin indirect 0.1 mg/dL, albumin 3.9 g/dL, prothrombin time 100%, alpha-fetoprotein 16.8 ng/dL, and carcinoembryonic antigen 1.7 ug/L, (Table 1). The other laboratory results were normal.

A computed tomography (CT) scan of the abdomen disclosed a large mass replacing the right lobe of the liver with no other abdominal masses or adenopathy. A chest CT scan was normal. Nuclear magnetic resonance study showed that the mass did not extend into the vena cava or the portal vein (Fig. 1). An arteriogram revealed normal hepatic arterial anatomy. A bone scan was negative for metastases.

Because of the favorable anatomic
location of the tumor and the absence of metastatic disease, an extended right hepatectomy was performed. The resection included the entire right lobe plus segment IVa and IVb. Both the right and middle hepatic veins were taken, leaving about 1 cm of liver tissue adjacent to the left hepatic vein. The abdominal exploration revealed no evidence of extrahepatic tumor or adenopathy.

After the final pathologic diagnosis, bone marrow and cerebral spinal fluid were examined and found to be free of disease. The patient had mild ascites and right pleural effusion that required pleural punctation because of restrictive pulmonary insufficiency. He was discharged from the hospital on the 14th postoperative day.

Postoperatively, the patient received systemic chemotherapy of cyclophosphamide, adriamycin, vincristine and prednisone. Twenty-four months after surgery, the patient continues to be free of disease.

**PATHOLOGIC STUDY**

The surgical specimen consisted of a right hepatic lobe plus segment IV, weighing 3340 g, and containing a neoplasm of 18 cm x 15.5 cm x 10 cm. The tumor appeared grayish white, soft, and homogenous, with focal hemorrhage and necrosis. Its border was well circumscribed and lobulated, and appeared to be completely within the limits of resection (Fig. 2).

Microscopically, the liver was composed of an infiltrative diffuse lymphoreticular neoplasia. There was a uniform population of lymphoid cells of large size with many mitotic figures (Fig. 3). The large neoplastic lymphoid cells immunostained positively for leukocyte common antigen and for B-cell markers including CD-20. CD-45RO–marked lymphocytes and CD-68–marked macrophages were present within the neoplasm.

The tumor was a large, lambda positive, CD-20 positive, anaplastic malignant B-cell lymphoma. Tests for CD-34, carcinoembryonic antigen, cytokeratin 7, alpha-protein, neurospecific actin, and enolase were negative.

**DISCUSSION**

The first report of primary hepatic lymphoma was by Ata and Kamal in 1965. Primary hepatic lymphoma has been reported in 48 patients. Only 2 of these previously reported cases have been children.

The review of the literature reveals that primary lymphoma of the liver occurs in a wide age range (7 to 84 years) and has been reported mainly in male patients. The gross involvement of the liver is of 1 or several nodules, and microscopically the dominant type is the large cell histiocytic type.

The cellular phenotype has been determined in 13 previous cases: 11 B-cell and 2 macrophage. None carried T-cell markers. The phenotype of one of the previous pediatric lymphomas was B-cell and the other was not determined.
The current case expressed B-cell but not T-cell or macrophage markers. The case satisfies the criteria for a primary hepatic lymphoma as described by Torres and Bollozos and more recently by Strayer et al.

The clinical presentation of primary lymphoma of the liver has been fairly uniform — middle-aged patients presenting with right upper quadrant or epigastric pain/discomfort in whom hepatomegaly or a tender mass is palpable.

Concerning hepatic resection, the perioperative strategies for reducing morbidity have improved significantly over recent years with a reduction of operative mortality to 3.7%.

In our case during surgery, there was no evidence of extrahepatic involvement, and the spleen was normal. There was no intra-abdominal adenopathy detected. Therefore, we performed an extended right hepatectomy.

The immediate postoperative period was uneventful except for both mild ascites and pleural effusion, which was treated clinically.

Multi-agent chemotherapy was started 3 weeks after the surgical procedure and was completed within 6 months. The patient was disease free 24 months after the treatment.

According to the more recent literature, treatment of primary hepatic lymphoma varies. For example, 1 patient treated with left hepatic lobectomy alone is disease free. The disease-free survival rate for 5 patients treated with resection and chemotherapy was 80%. Of 13 patients treated with chemotherapy alone, 54% are disease free.

Two cases reported by Leahy et al. were treated with chemotherapy; 1 patient had a complete remission and 1 a partial remission.

The importance of surgical resection in localized disease thereby affording a cure or at least a reduction of tumor burden cannot be assessed in this limited series.

Whether or not systemic treatment with chemotherapy will give comparable results to surgery in resectable cases is also not currently known. It seems reasonable to first treat these patients with systemic chemotherapy. If disease persists or only partially regresses in the liver, and there is no evidence of extrahepatic involvement, surgical resection can be performed.

We did not perform surgery in this case, because of the extent of the disease, which had spread almost throughout the whole liver (segments IV, V, VI, VII, and VIII).

Many kinds of treatment, such as chemotherapy, radiation therapy, and percutaneous ethanol injection
therapy, have been reported for primary malignant lymphoma of the liver. Previous reports\(^7\),\(^8\),\(^15\),\(^18\),\(^22\),\(^24\),\(^28\) of 15 patients who underwent hepatic resection are reviewed (Table 2). With the exception of 3 cases, all cases received multi-agent chemotherapy postoperatively. Fourteen were alive at the time of their respective case reports, at intervals ranging from 5 to 124 months (mean 39 months).

Pescovitz et al.\(^24\) noted that the disease-free survival rate for 5 patients treated with resection and combined chemotherapy was 80%, compared with 54% survival for chemotherapy alone.

In conclusion, although we do not deny the effectiveness of chemotherapy as shown in some reports\(^7\),\(^30\),\(^31\), we consider hepatic resection combined with chemotherapy to be the best method of therapy for this disease in the absence of any extra-hepatic lesions.

### Table 2. Surgically resected primary malignant lymphoma of the liver in the literature.

<table>
<thead>
<tr>
<th>No</th>
<th>Literature</th>
<th>Age, Sex</th>
<th>Chief complaint</th>
<th>LDH (IU/L)</th>
<th>Tumor Location</th>
<th>Size (cm)</th>
<th>Surgery</th>
<th>Adjuvant Therapy</th>
<th>Prognosis (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Daniel</td>
<td>60, F</td>
<td>Fever up</td>
<td>ND</td>
<td>Bilateral lobes</td>
<td>10x10</td>
<td>Extended lt lobectomy</td>
<td>None</td>
<td>22, alive</td>
</tr>
<tr>
<td>2</td>
<td>Osborne</td>
<td>48, F</td>
<td>RUQ pain</td>
<td>124</td>
<td>ND</td>
<td>4x10</td>
<td>Excised</td>
<td>Chemo</td>
<td>124, alive</td>
</tr>
<tr>
<td>3</td>
<td>Osborne</td>
<td>58, M</td>
<td>Abdominal pain</td>
<td>277</td>
<td>Lt. lobe</td>
<td>11x10</td>
<td>Excised</td>
<td>Chemo</td>
<td>20, alive</td>
</tr>
<tr>
<td>4</td>
<td>Ryoo</td>
<td>23, M</td>
<td>RUQ pain</td>
<td>ND</td>
<td>Rt. lobe</td>
<td>7x6x4</td>
<td>Rt. Lobectomy</td>
<td>none</td>
<td>18, alive</td>
</tr>
<tr>
<td>5</td>
<td>Redondo</td>
<td>24 F</td>
<td>Epigastric pain</td>
<td>ND</td>
<td>Lt. lobe</td>
<td>ND</td>
<td>Lt. Lobectomy</td>
<td>Chemo</td>
<td>21, alive</td>
</tr>
<tr>
<td>6</td>
<td>Ryan</td>
<td>65, M</td>
<td>Epigastric discomfort</td>
<td>531</td>
<td>Rt. lobe</td>
<td>30x25</td>
<td>Trisegmentectomy</td>
<td>Chemo</td>
<td>61, alive</td>
</tr>
<tr>
<td>7</td>
<td>Ryan</td>
<td>57, M</td>
<td>Lethargy</td>
<td>233</td>
<td>Rt. lobe</td>
<td>11x9x5</td>
<td>Trisegmentectomy</td>
<td>Chemo</td>
<td>15, died</td>
</tr>
<tr>
<td>8</td>
<td>Ryan</td>
<td>49, M</td>
<td>RUQ pain</td>
<td>248</td>
<td>Rt. lobe</td>
<td>10</td>
<td>Trisegmentectomy</td>
<td>Chemo+ radiation</td>
<td>61, alive</td>
</tr>
<tr>
<td>9</td>
<td>Ryan</td>
<td>36, M</td>
<td>RUQ pain</td>
<td>438</td>
<td>Rt. lobe</td>
<td>15x15</td>
<td>Rt. Lobectomy</td>
<td>Chemo</td>
<td>53, alive</td>
</tr>
<tr>
<td>10</td>
<td>Millis</td>
<td>11, M</td>
<td>Abdominal swelling</td>
<td>Normal</td>
<td>Rt. lobe</td>
<td>19x17x12</td>
<td>Rt. Lobectomy</td>
<td>Chemo</td>
<td>30, alive</td>
</tr>
<tr>
<td>11</td>
<td>Andreola</td>
<td>22, M</td>
<td>RUQ pain jaundice</td>
<td>ND</td>
<td>Rt. lobe</td>
<td>10</td>
<td>Trisegmentectomy</td>
<td>None</td>
<td>62, alive</td>
</tr>
<tr>
<td>12</td>
<td>Pescowitz</td>
<td>17, M</td>
<td>Epigastric mass</td>
<td>3770</td>
<td>Lt. lobe+S8</td>
<td>16x14x10</td>
<td>Lt. Lobectomy S8 partial</td>
<td>Chemo</td>
<td>12, alive</td>
</tr>
<tr>
<td>13</td>
<td>Hida</td>
<td>45, M</td>
<td>Epigastric pain</td>
<td>910</td>
<td>Lt. lateral lobe</td>
<td>15x10x7</td>
<td>Lt. Lateral segmentectomy</td>
<td>Chemo</td>
<td>6, alive</td>
</tr>
<tr>
<td>14</td>
<td>Mitsui</td>
<td>58, M</td>
<td>RUQ pain</td>
<td>202</td>
<td>Lt. lobe</td>
<td>10x7x7</td>
<td>Lt. Lobectomy</td>
<td>Chemo</td>
<td>36, alive</td>
</tr>
<tr>
<td>15</td>
<td>Taketomi</td>
<td>51, M</td>
<td>Free</td>
<td>1180</td>
<td>Rt. lobe</td>
<td>7x6x4</td>
<td>Extended rt. Lobectomy</td>
<td>Chemo</td>
<td>45, alive</td>
</tr>
<tr>
<td>16</td>
<td>Our case</td>
<td>33, M</td>
<td>Lethargy, weight loss</td>
<td>1190</td>
<td>Rt. Lobe + S1</td>
<td>26x22x10</td>
<td>Trisegmentectomy</td>
<td>Chemo</td>
<td>24, alive</td>
</tr>
</tbody>
</table>

ND: not described, LDH: lactic dehydrogenase, RUQ: right upper quadrant, Rt.: right, Lt.: left, Chemo: chemotherapy, M: male, F: female.
RESUMO


O linfoma primário do fígado é uma entidade extremamente rara. Os autores relatam um caso de linfoma não-Hodgkin de células B grandes anaplasticas (positivo para CD-20 e Lambda) em um paciente do sexo masculino de 33 anos. O tumor estava localizado no lobo hepático direito e foi tratado por hepatectomia direita ampliada e quimioterapia pós-operatória com ciclofosfamida, Adriamicina, vincristina e prednisone.

Vinte quatro meses de seguimento o paciente encontra-se sem recidiva tumoral.


REFERENCES

5. STRAYER DS, REPPUN TS, LEVIN M et al. - Primary lymphoma of the liver. Gastroenterology 1980; 78:1571-76.


27. NISHIZAKI T, MATSUMATA T, KAWAKURA T et al. – Significance of intraoperative measurement of the liver consistency prior to hepatic resection. Hepatogastroenterol 1995; 42: 5-8.

28. HIGASHI H, ADACHI E, MATSUMATA T et al. – Influence of hepatectomy on cell infiltration in the resected liver parenchyma compared with the biopsy specimen – a preliminary study. Hepatogastroenterol 1994; 41: 162-64.


Received for publication on September 28, 2002.